COVID-19 in 96 Patients With Hematologic Disease: The First Single-center Experience From the Czech Republic

Čerňan, Martin; Szotkowski, Tomáš; Obr, Aleš; Látal, Vojtěch; Hluší, Antonín; Krhovská, Petra; Klementová, Olga; Kolář, Milan; Šauer, Pavel; Faber, Edgar; Fürst, Tomáš; Papajík, Tomáš

doi:10.1016/j.clml.2021.04.016

Cited by 3 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most common and most important laboratory abnormalities in this study were leucopenia and lymphopenia at the time of COVID-19 diagnosis with a median count of 0.8 in patients who underwent BMT, 0.7 in patients with the hematological disease, and 1 in the control group and when we compared it between different groups we found a statistically significant difference between groups according to WBCs, Neutrophils Hb and Platelets ( as it was highest in hematological patients, and control patients and within normal in BMT patients ), in contrary to Čerňan et al (8) , who did not find any statistically significant difference of other CBC parameter while in Wang et al (10) most patients had normal the leukocyte count and lymphocyte count was generally reduced.…”

Section: Discussioncontrasting

confidence: 89%

“…The severity of COVID-19 was defined as mild (no oxygen supplementation), moderate (supplemental oxygen needed), or severe (mechanical ventilation required) (7) . Duration of disease was defined as the time from diagnosis to infection resolution or death, and infection status at last follow-up was as reported by the infection control center (8) . Indeed, our high-risk population underwent closer monitoring than the rest of the population who, according to the national government provisions, was not subjected to an intensive diagnostic strategy, particularly in the presence of mild symptoms.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparative study between COVID-19 Outcomes for Patients on Chronic Immunosuppressive Drugs, Patients on Active chemotherapy and Non- Immunosuppressed Patients: A Single-Center Egyptian Experience

Khalifa¹,

Moussa²,

Mohamed³

2022

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Patients with hematological disorders especially those who underwent bone marrow transplantation are known for having some degree of immune system derangement and cytokine signaling instability as well as patients who were diagnosed with active malignancy and needed chemotherapy.Objective: The study aimed to compare the outcome between patients infected with COVID 19 who use immune suppression (either acute or chronic immune suppression) to fight COVID infection and how our different bodies and immune systems can handle it versus the normal population. Patients and Methods: This study was a cross-sectional study in December 2020 conducted on 96 subjects who caught COVID-19 infection, the subjects were categorized into three groups: Group 1: consists of 32 patients who underwent BMT (patients on chronic immunosuppressive drugs), Group 2: consists of 32 patients with hematological diseases (patients on chemotherapy or acute immunosuppressive drugs), and Group 3: control group (non-immunosuppressed patients) consists of 32 patients with patients had symptomatic COVID-19 infections requiring hospital admission. Results: We found improved overall survival in group 1 with 4 out of the total 32 patients succumbed to their deaths, 2 of the 4 patients were in the peri-engraftment period with the statistically significant improved OS when compared to patients in group 2 with a P-value of 0.038. Conclusion: Acute immune suppression is done by chemotherapy worsen the outcome of COVID-19 infection, while chronic immunosuppression had the best outcome in COVID-19 patients even better than the normal population due to loss of immune cell signaling and absent cytokines storm that might occur.

show abstract

Section: Discussioncontrasting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Comparative study between COVID-19 Outcomes for Patients on Chronic Immunosuppressive Drugs, Patients on Active chemotherapy and Non- Immunosuppressed Patients: A Single-Center Egyptian Experience

Khalifa¹,

Moussa²,

Mohamed³

2022

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

show abstract

“…The data obtained were analysed and compared with our own historical cohort of 96 patients with haematologic malignancies and bone marrow failure syndromes (2 patients) who were treated for COVID-19 in the period from 1 March 2020 to 31 December 2020 and did not undergo vaccination. Detailed information about the cohort was published by Čerňan et al [ 17 ].…”

Section: Methodsmentioning

confidence: 99%

Breakthrough COVID-19 in Vaccinated Patients with Haematologic Malignancies—The First Single-Centre Experience from the Czech Republic

Čerňan

Szotkowski

Minařík

et al. 2022

Life

Self Cite

View full text Add to dashboard Cite

Vaccination is an important tool in the fight against the COVID-19 pandemic in patients with haematologic malignancies. The paper provides an analysis of the course of breakthrough SARS-CoV-2 infection in a group of vaccinated patients with haematological malignancy and a comparison with a historical cohort of 96 non-vaccinated patients with haematologic malignancies and bone marrow failure syndromes (two patients) in the treatment of COVID-19. A severe or critical course of COVID-19 was significantly less frequent in the group of vaccinated patients (10.2% vs. 31.4%, p = 0.003). The need for hospitalisation due to COVID-19 was significantly lower in vaccinated patients (27.1% vs. 72.6%, p < 0.0001) and the duration of hospitalisation was significantly shorter (10 vs. 14 days, p = 0.045). Vaccinated patients were insignificantly less likely to require oxygen therapy during infection. COVID-19 mortality was significantly higher in non-vaccinated patients (15.6% vs. 5.1%, p = 0.047). The paper demonstrated a significant positive effect of vaccination against COVID-19 on a less severe clinical course of infection, lower need for hospitalisation and mortality. However, the results need to be evaluated even in the context of new antivirals and monoclonal antibodies against SARS-CoV-2 or virus mutations with different biological behaviour.

show abstract

COVID-19 in patients with hematologic malignancy

Langerbeins

Hallek

2022

Blood

View full text Add to dashboard Cite

The coronavirus infectious disease (COVID-19) shows a remarkable symptomatic heterogeneity. Several risk factors including advanced age, previous illnesses and a compromised immune system contribute to an unfavorable outcome. In patients with hematologic malignancy, the immune response to severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is significantly reduced explaining why the mortality rate of hematologic patients hospitalized for a SARS-CoV-2 infection is about 34%. Active immunization is an essential pillar to prevent SARS-CoV-2 infections in patients with hematologic malignancy. However, the immune response to SARS-CoV-2 vaccines may be significantly impaired, as only half of patients with hematologic malignancy develop a measurable anti-viral antibody response. The subtype of hematologic malignancy and B-cell depleting treatment predict a poor immune response to vaccination. Recently, antiviral drugs and monoclonal antibodies for pre-exposure or post-exposure prophylaxis and for early treatment of COVID-19 have become available. These therapies should be offered to patients at high risk for severe COVID-19 and vaccine non-responder. Importantly, as the virus evolves, some therapies may lose their clinical efficacy against new variants. Therefore, the ongoing pandemic will remain a major challenge for patients with hematologic malignancy and their caregivers who need to constantly monitor the scientific progress in this area.

show abstract

COVID-19 in 96 Patients With Hematologic Disease: The First Single-center Experience From the Czech Republic

Cited by 3 publications

References 20 publications

Comparative study between COVID-19 Outcomes for Patients on Chronic Immunosuppressive Drugs, Patients on Active chemotherapy and Non- Immunosuppressed Patients: A Single-Center Egyptian Experience

Comparative study between COVID-19 Outcomes for Patients on Chronic Immunosuppressive Drugs, Patients on Active chemotherapy and Non- Immunosuppressed Patients: A Single-Center Egyptian Experience

Breakthrough COVID-19 in Vaccinated Patients with Haematologic Malignancies—The First Single-Centre Experience from the Czech Republic

COVID-19 in patients with hematologic malignancy

Contact Info

Product

Resources

About